RPG Life SciencesNSE:RPGLIFE +0.92%94 Days Payable is 146.46 as of Mar. 2026, which is 20% above its 10-year median of 122.19. GuruFocus rates NSE:RPGLIFE with a GF Score™ of 94/100 and a GF Value™ of ₹2,352.95 (Fairly Valued). The stock has 5 warning signs investors should review. Among 922 Drug Manufacturers companies, RPG Life Sciences ranks better than 70.07% on this metric.
The historical rank and industry rank for RPG Life Sciences's Days Payable or its related term are showing as below:
NSE:RPGLIFE'
s Days Payable Range Over the Past 10 Years
Min: 94.23 Med: 122.19 Max: 132.51
Current: 132.51
During the past 13 years, RPG Life Sciences's highest Days Payable was 132.51. The lowest was 94.23. And the median was 122.19.
NSE:RPGLIFE's Days Payable is ranked better than 70.07% of 922
companies
in the Drug Manufacturers industry
Industry Median: 90.61
vs NSE:RPGLIFE: 132.51
RPG Life Sciences's Days Payable
declined
from Mar. 2025 (148.69) to Mar. 2026 (146.46).
It may suggest that RPG Life Sciencesaccelerated paying its suppliers.
RPG Life Sciences Days Payable Related Terms
RPG Life Sciences Days Payable Historical Data
* Premium members only.
The historical data trend for RPG Life Sciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, RPG Life Sciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RPG Life Sciences Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, RPG Life Sciences's Days Payable distribution charts can be found below:
* The bar in red indicates where RPG Life Sciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
RPG Life Sciences's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RPG Life Sciences (NSE:RPGLIFE) has a Days Payable of 146.46 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on RPG Life Sciences and its competitors. This is 20% above median its historical median of 122.19. Over the past decade, RPG Life Sciences' Days Payable has ranged from 94.23 to 132.51. According to the industry distribution chart, RPG Life Sciences ranks #276 out of 922 companies in the Drug Manufacturers industry, placing it in the top 29.9%.
Is RPG Life Sciences' Days Payable too high?
RPG Life Sciences' current Days Payable of 146.46 is 20% above median its 10-year median of 122.19. Over the past 10 years, this metric has ranged from a low of 94.23 to a high of 132.51. The Drug Manufacturers industry median Days Payable is 90.61. RPG Life Sciences' value of 146.46 is 61.6% above this industry median. Based on the distribution chart, RPG Life Sciences ranks #276 out of 922 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, RPG Life Sciences has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does RPG Life Sciences' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, RPG Life Sciences ranks #276 out of 922 companies for Days Payable. This puts RPG Life Sciences in the upper half of its industry. The industry median Days Payable is 90.61. RPG Life Sciences' value of 146.46 is 61.6% above this benchmark. Historically, RPG Life Sciences' own Days Payable has ranged from 94.23 to 132.51 over the past decade. While the company's 10-year median is 122.19 vs. the industry median of 90.61, RPG Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.61, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RPG Life Sciences's current Days Payable of 146.46 is 61.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on RPG Life Sciences and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RPG Life Sciences's current Days Payable is 146.46, which is 20% above median its own 10-year median of 122.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RPG Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, RPG Life Sciences (NSE:RPGLIFE) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,352.95, compared to a current price of ₹2,415.80 — trading 2.7% above its estimated fair value. The current Days Payable is 146.46, which is 20% above median its 10-year median of 122.19 and 61.6% above the Drug Manufacturers industry median of 90.61. RPG Life Sciences' overall GF Score™ is 94/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For RPG Life Sciences (NSE:RPGLIFE), the current Days Payable is 146.46 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RPG Life Sciences (NSE:RPGLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, RPG Life Sciences stock appears to be overvalued.
The current stock price of ₹2,415.80 is trading 2.7% above its estimated GF Value™ of ₹2,352.95.
GuruFocus considers RPG Life Sciences to be Fairly Valued.
Key valuation signals for NSE:RPGLIFE:
Days Payable: 146.46 (20% above median its 10-year median of 122.19)
GF Value™: ₹2,352.95 vs. price of ₹2,415.80 (2.7% above fair value)
Industry Position: 61.6% above the Drug Manufacturers median (#276 of 922)
No single metric tells the full story. See the NSE:RPGLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RPG Life Sciences Ltd is an integrated pharmaceutical company. Its only reportable segment is the manufacturing and marketing of pharmaceutical products. Geographically, it derives a majority of revenue from India. The company operates across Domestic Formulations, International Formulations and Active Pharmaceutical Ingredients (API). It focuses on Nephrology, Oncology, Urology, Respiratory, Gastrointestinal, Cardiovascular, Gynaecology and Pediatrics, Vitamins and Minerals, Pain Management, Neurology, Anti-Dengue, Anti-Diabetic, and Derma.
94GF Score
Get the complete analysis for NSE:RPGLIFE
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:RPGLIFE has been successfully added to your 
